Model N Fall 2022 Product Offering Addresses Dynamic Market Needs

Rhea-AI Summary

Model N, Inc. (NYSE: MODN) has announced its Fall 2022 product release of the Model N Revenue Cloud, focusing on revenue optimization and compliance for life sciences and high-tech sectors. The update offers enhancements aimed at improving profitability and strategic objectives for pharmaceutical and medtech companies, including better revenue forecasting and Medicaid rebate calculations. Additionally, high-tech firms benefit from a 25% improvement in rebate calculation performance. These enhancements are designed to help clients quickly adapt to market changes amid rising economic pressures.

Positive

• 25% improvement in rebate calculation performance for high-tech companies.
• Enhancements aimed at better revenue forecasting and compliance for pharmaceutical clients.
• New tools to support strategic objectives and profitability for life sciences companies.

Negative

• None.

Revenue optimization and compliance leader delivers market-ready tools to support shifting priorities for life sciences and high-tech companies

SAN MATEO, Calif.--(BUSINESS WIRE)-- Model N, Inc. (NYSE: MODN), the leader in revenue optimization and compliance, today announced its Fall 2022 product release of the Model N Revenue Cloud. This latest semi-annual update focuses on bringing innovative revenue optimization and compliance solutions for life sciences and high-tech customers, informed by market shifts, customer feedback, and the continuous pursuit of marketplace excellence.

“Today’s life sciences and high-tech innovators are feeling the pressure of an ever-changing market economy to act quickly while maintaining compliance. To empower our customers to keep thriving and making business critical decisions, Model N’s newest product enhancements were built to power our customers’ innovation, profitability, and business growth,” said Suresh Kannan, Chief Product Officer, Model N.

Enhancing Profitability for Life Sciences

The latest life sciences enhancements will help pharmaceutical and medtech manufacturers achieve compliance and more quickly meet their strategic objectives. Model N’s customers will be able to better forecast the revenue and pricing impacts of a drug falling off patent, ensure they are able to receive and process the latest payer, prescriber, and government data standards, and more accurately calculate Medicaid rebates. Combined with the increased ability to control contract pricing communication with internal and external parties, companies can be confident the right products are delivered to the right providers at the right prices. Additionally, customers will have critical performance metrics at their fingertips—showcasing contracted sales and overall savings trends, chargebacks and rebates, and fee savings.

Proactive Market Response for High-Tech

An important benefit for high-tech companies is a 25% improvement in rebate calculation performance for high data volumes, delivering more scalability in an expanding partner ecosystem. Companies will also be able to more quickly execute price updates in current deals and apply new pricing to future deals – critical given the current economic outlook. Customers will have more flexibility in channel data automation, allowing them to manage and reconcile data independently. These enhancements are critical for customers needing to take quicker action to respond to market changes including inflation and fluidity in supply and demand.

“As data standards and market dynamics evolve, our customers expect more out of technology partners to help them stand out and power innovation,” said Karim Damji, SVP, Product Management, Model N. “Model N’s deep industry knowledge and market-proof technology equip customers with essential revenue optimization and compliance tools for today’s fluid market.”

To learn more about the Model N Fall 2022 product release, visit www.modeln.com.

About Model N

Model N is the leader in revenue optimization and compliance for pharmaceutical, medtech and high-tech innovators. Our intelligent platform powers your digital transformation with integrated technology, data, analytics, and expert services that deliver deep insight and control.

Our integrated cloud solution is proven to automate pricing, incentive and contract decisions to scale business profitably and grow revenue. Model N is trusted across more than 120 countries by the world’s leading pharmaceutical, medical technology, semiconductor, and high-tech companies, including Johnson & Johnson, AstraZeneca, Stryker, Seagate Technology, Broadcom, and Microchip Technology. For more information, visit www.modeln.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221115005408/en/

Media Contacts:

Public Relations

BLASTmedia

press@modeln.com

Investor Relations

Market Street Partners

Investorrelations@modeln.com

Source: Model N, Inc.

FAQ

What is the latest product release from Model N, Inc. involving MODN?

Model N, Inc. announced its Fall 2022 product release of the Model N Revenue Cloud, focusing on revenue optimization and compliance for its clients.

How does Model N's product enhance profitability for life sciences companies?

The latest updates help pharmaceutical firms improve revenue forecasting, streamline Medicaid rebate calculations, and optimize contract pricing communication.

What benefits do high-tech companies receive from the new Model N product release?

High-tech companies experience a 25% improvement in rebate calculation performance and enhanced flexibility in managing channel data.

How does Model N support its clients in responding to market changes?

Model N's enhancements allow clients to quickly adapt pricing in response to economic changes and maintain compliance with evolving market standards.